Camposomes are phospholipid nanoencapsulated camptothecins used to treat pancreatic and other cancers. The subcontract is in support of the National Cancer Institute (NCI) Alliance for Nanotechnology, and the aim is to evaluate the potential of Aphios’ enabling nanotechnologies to improve the bioavailability, solubility, pharmacokinetics, or therapeutic index of a range of drugs that would otherwise fail as anti-cancer agents.
Aphios has utilised its patented SuperFluids CFN technologies to develop nanosomal formulations of paclitaxel , camptothecin and other poorly water-soluble therapeutics. It is anticipated that further research will improve the efficacy, reduce the toxicity, and improve the solubility and stability of this topoisomerase I inhibitor and anticancer drug.